71605-72-6

Basic information

• Product Name: 2,1,3-Benzothiadiazole-5-carbaldehyde
• Synonyms: BUTTPARK 75\50-32;2,1,3-BENZOTHIADIAZOLE-5-CARBALDEHYDE;2,1,3-BENZOTHIADIAZOLE-5-CARBOXALDEHYDE;Benzo[1,2,5]thiadiazole-5-carbaldehyde;benzo[c][1,2,5]thiadiazole-5-carbaldehyde;2,1,3-benzothiadiazole-5-carbaldehyde(SALTDATA: FREE);5-ForMyl-2,1,3-benzothiadiazole;2,1,3-benzothiadiazole-6-carbaldehyde
• CAS NO: 71605-72-6
• Molecular Formula: C₇H₄N₂OS
• Molecular Weight: 164.18
• Mol File: 71605-72-6.mol

Chemical Properties

• Melting Point: 90 °C
• Boiling Point: 291.9 °C at 760 mmHg
• Flash Point: 130.3 °C
• Appearance: /
• Density: 1.477 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.753
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.78±0.36(Predicted)
• CAS DataBase Reference: 2,1,3-Benzothiadiazole-5-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2,1,3-Benzothiadiazole-5-carbaldehyde(71605-72-6)
• EPA Substance Registry System: 2,1,3-Benzothiadiazole-5-carbaldehyde(71605-72-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-41-37/38
• Safety Statements: 26-36/37/39-24/25-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 71605-72-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2,1,3-Benzothiadiazole-5-carbaldehyde is used as a building block in organic synthesis for its ability to form a variety of complex organic compounds, contributing to the development of new materials and chemical entities.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 2,1,3-Benzothiadiazole-5-carbaldehyde is used as a key intermediate in the synthesis of drugs, leveraging its electron-accepting properties to enhance the pharmacological activity of the resulting compounds.
Used in Dye Manufacturing:
2,1,3-Benzothiadiazole-5-carbaldehyde is utilized as a component in the production of dyes, where its aromatic structure and color-yielding properties are harnessed to create a range of dye products.
Used in Agrochemicals:
This chemical compound is employed in the development of agrochemicals, where its properties can be tailored to target specific pests or enhance crop protection.
Used in Organic Electronic Devices:
2,1,3-Benzothiadiazole-5-carbaldehyde is used as a component in the fabrication of organic electronic devices such as OLEDs and organic photovoltaic cells, capitalizing on its strong electron-accepting properties and high electron mobility to improve device performance.
Used in Drug Development:
Due to its bioactive properties, 2,1,3-Benzothiadiazole-5-carbaldehyde is explored for its potential in the development of new drugs and biologically active compounds, offering a promising avenue for pharmaceutical innovation.

InChI:InChI=1/C7H4N2OS/c10-4-5-1-2-7-6(3-5)8-9-11-7/h1-4H

Upstream product

• 1457-93-8 5-methylbenzo[c][1,2,5]thiadiazole 
• 175204-21-4 methyl benzo-2,1,3-thiadiazole-5-carboxylate 
• 36692-49-6 Methyl 3,4-diaminobenzoate 
• 619-05-6 3,4-diaminobenzoic acid 
• 65858-50-6 5-bromomethyl-benzo[1,2,5]thiadiazole 
• 89795-51-7 2,1,3-benzothiadiazol-5-ylmethanol 
• 71605-71-5 N'-benzo[1,2,5]thiadiazol-5-ylmethylene-N,N-dimethyl-benzene-1,4-diamine N'-oxide 

Downstream Products

• 16405-98-4 benzo[c][1,2,5]thiadiazole-5-carboxylic acid 
• 71605-70-4 5-thiazolidin-2-yl-benzo[1,2,5]thiadiazole 
• 89795-51-7 2,1,3-benzothiadiazol-5-ylmethanol 
• 364050-15-7 1-(benzo[c] [1,2,5]thiadiazol-5-yl)-2-(6-methylpyridin-2-yl)ethane-1,2-dione 
• 949465-70-7 2-(2-bromo-phenylamino)-5-(3,4-diamino-benzylidene)-thiazol-4-one 
• 1367578-55-9 5-(benzo[c][1,2,5]thiadiazol-5-ylmethylene)-3-benzyl-2-thioxothiazolidin-4-one 
• 1018814-89-5 (6R,12aR)-6-benzo[1.2.5]thiadiazol-5-yl-2-((R)-1-benzylpyrrolidin-3-yl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione 
• 1018814-90-8 (6S,12aR)-6-benzo[1,2,5]thiadiazol-5-yl-2-((R)-1-benzylpyrrolidin-3-yl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione 
• 66669-21-4 C₁₄H₁₁N₃ 
• 1024609-19-5 5-(benzo[c][1,2,5]thiadiazol-5-yl)-1-(1H-benzo[d]imidazol-5-yl)-3-hydroxy-4-(3-hydroxyphenyl)-1H-pyrrol-2(5H)-one 
• 701293-60-9 5-benzo[1,2,5]thiadiazol-5-ylmethylene-2-(2-bromophenylimino)-thiazolidin-4-one 

Relevant articles and documents

A “universal” catalyst for aerobic oxidations to synthesize (hetero)aromatic aldehydes, ketones, esters, acids, nitriles, and amides

Functionalized (hetero)aromatic compounds are indispensable chemicals widely used in basic and applied sciences. Among these, especially aromatic aldehydes, ketones, carboxylic acids, esters, nitriles, and amides represent valuable fine and bulk chemicals, which are used in chemical, pharmaceutical, agrochemical, and material industries. For their synthesis, catalytic aerobic oxidation of alcohols constitutes a green, sustainable, and cost-effective process, which should ideally make use of active and selective 3D metals. Here, we report the preparation of graphitic layers encapsulated in Co-nanoparticles by pyrolysis of cobalt-piperazine-tartaric acid complex on carbon as a most general oxidation catalyst. This unique material allows for the synthesis of simple, functionalized, and structurally diverse (hetero)aromatic aldehydes, ketones, carboxylic acids, esters, nitriles, and amides from alcohols in excellent yields in the presence of air.

N-SUBSTITUTED-3,4-(FUSED 5-RING)-5-PHENYL-PYRROLIDINE-2-ONE COMPOUNDS AS INHIBITORS OF ISOQC AND/OR QC ENZYME

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidin-2-one compounds (also referred to herein as "FRPPO compounds"), that, inter alia, inhibit glutaminyl-peptide cyclotransferase-like (isoQC) enzyme and/or glutaminyl-peptide cyclotransferase (QC) enzyme (e.g., inhibit or reduce or block the activity or function of isoQC and/or QC enzyme). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit isoQC and/or QC enzyme; to treat disorders that are ameliorated by the inhibition of isoQC and/or QC enzyme; to treat cancer, atherosclerosis, fibrotic diseases, infectious diseases, Alzheimer's disease, etc.

NEW PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS

The present invention describes new pyridopyrimidine derivatives compounds with structure represented by General Formula (I): or pharmaceutically acceptable salts thereof, or their mixtures (in any ratio), a pharmaceutical composition containing them, a method for using the new pyridopyrimidine derivatives compounds as inhibitor of the cyclic nucleotide synthesis or as inhibitor of the cAMP and cGMP synthesis, and their uses in the prophylactic and/or curative treatment of diarrhea, colitis and irritable bowel syndrome.

Cytotoxic activities and metabolic studies of new combretastatin analogues

A new series of combretastatin analogues with B-ring modifications were synthesized and evaluated for their cytotoxicity against one endothelial (HUVEC) and three tumor cell lines, e.g., the LoVo colon, the PC-3 prostate, and the U373 glioma cancer models. These new combretastatin analogues showed differential cytotoxic activities, cis derivatives 13 5-(2-Z-trimethoxyphenylethenyl)benzo[1,2-c]1,2,5-oxadiazole N 1-oxide and 14 5-(2-Z-trimethoxyphenylethenyl)benzo[1,2,5]thiadiazole exhibiting interesting cytotoxicity both on endothelial and on tumor cells. Unlike the cis benzofurazan 12 5-(2-Z-trimethoxyphenylethenyl)benzo[1,2-c]1,2,5-oxadiazole, induction of apoptosis by 13 appeared to be through caspase-3 activation. Metabolic investigations showed a positive correlation between highly metabolized compounds and cytotoxic activity, suggesting that highly cytotoxic derivatives may act as pro-drug via a reductive metabolization to more active metabolites.

Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinoline-8(4H)-one 1,1-dioxide K ATP channel openers: Discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b] quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent KATP opener that selectively inhibits spontaneous bladder contractions

Structure-activity relationships were investigated on a novel series of sulfonyldihydropyridine-containing KATP openers. Ring sizes, absolute stereochemistry, and aromatic substitution were evaluated for K ATP activity in guinea pig bladder cells using a fluorescence-based membrane potential assay and in a pig bladder strip assay. The inhibition of spontaneous bladder contractions in vitro was also examined for a select group of compounds. All compounds studied showed greater potency to inhibit spontaneous bladder contractions relative to their potencies to inhibit contractions elicited by electrical stimulation. In an anesthetized pig model of myogenic bladder overactivity, compound 14 and (-)-cromakalim 1 were found to inhibit spontaneous bladder contractions in vivo at plasma concentrations lower than those that affected hemodynamic parameters. Compound 14 showed approximately 5-fold greater selectivity than 1 in vivo and supports the concept that bladder-selective KATP channel openers may have utility in the treatment of overactive bladder.

NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS

Cyclohexane and cyclohexene derivatives and pharmaceutically acceptable derivatives hereof useful in methods of treatment of bacterial infections in mammals, particularly man.

Potassium channel openers

Compounds having the formula I: are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.